Table 1 Demographic, clinical and autoantibody profile of patients whose CSF samples were used in the study
NMO | CNS SLE #1 | CNS SLE #2 | CNS SLE #3 | CNS SLE #4 | |
|---|---|---|---|---|---|
Age | 52 | 59 | 60 | 65 | 49 |
Sex | Female | Female | Female | Female | Female |
SLE duration (years) | 0 | 6 | 19 | 9 | 8 |
SLEDAI | 0 | 12 | 12 | 9 | 12 |
Neuropsychiatric manifestations | None | Psychosis Cognitive Dysfunction Vasculitis | Headaches Vasculitis | Depression Cognitive Dysfunction Vasculitis | Anxiety Cerebrovascular Diseases |
Serum ANA staining pattern | Negative | Homogenous + | Homogenous +++ | Homogenous ++ | Speckle +++ |
Serum anti-AQP4 Positivity | Positive | Negative | Negative | Negative | Negative |
Serum anti-dsDNA (g/l) | Negative | 163.72 | 514.44 | 297.88 | 25.7 |
CSF anti-dsDNA (g/l) | Negative | 49.46 | 253.61 | 77.85 | 13.46 |